Skip to main content
. 2018 Aug 4;16:76–87. doi: 10.1016/j.molmet.2018.07.013

Figure 3.

Figure 3

KDT501 acts as a GLP-1 secretagogue to improve glucose homeostasis. (A) Effect of a single oral dose of KDT501 on GLP-1 circulating levels in naïve DIO mice (n ≥ 7). (B) Glucose tolerance test in naïve DIO mice after a single dose of KDT501 administered 30 min prior to an oral glucose bolus (n ≥ 7). (C) Plasma GLP-1 levels in DIO mice treated with 150 mg/kg KDT501 for 4 days and dosed 30 min prior to blood collection in tubes containing a DPP-IV inhibitor (n ≥ 8). (D) Plasma glucose and insulin levels, and HOMA-IR in fasted DIO mice after 4 days of 150 mg/kg KDT501 treatment (n ≥ 8). Data presented as means ± SEM. Statistical significance was calculated using two-way ANOVA in A–B, and Student's t test in C–D. *p < 0.05, **p < 0.01, ***p < 0.001 relative to vehicle-treated mice.